| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:10210696 | IVR | 0.037 mg/kg/day | 0.037 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.037 mg/kg/day | 0.037 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.37 mg/kg/day | 0.37 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.37 mg/kg/day | 0.37 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0037 mg/kg/day | 0.0037 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0037 mg/kg/day | 0.0037 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:10377036 | IVR | 33 mg/kg | 33 mg/kg | Changes in morphology of accessory sex organs | Reproductive endocrine-mediated perturbations |
| IVR | 33 mg/kg | 33 mg/kg | Uterine hyperplasia | Reproductive endocrine-mediated perturbations | |
| PMID:10397250 | IVR | 25 mg | 25 mg | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 25 mg | 25 mg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| PMID:10641015 | IVR | 0.04 mg/kg | 0.04 mg/kg | Decreased weights of accessory sex organs | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Alterations in preputial separation | Reproductive endocrine-mediated perturbations | |
| PMID:10908838 | IVR | 1 mg/kg/day | 1 mg/kg/day | Testicular atrophy | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| PMID:11229807 | IVR | 0.001 mg/kg | 0.001 mg/kg | Increased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects epididymis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Changes in epididymal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations | |
| PMID:11961216 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Decreased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0002 mg/kg/day | 0.0002 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| PMID:12446607 | IVR | 0.0001 mg | 0.0001 mg | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg | 0.0001 mg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg | 0.0001 mg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:12520077 | IVR | 0.01 mg/kg | 0.01 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:12589653 | IVR | 0.005 mg | 0.005 mg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.005 mg | 0.005 mg | Affects sperm maturation in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg | 0.005 mg | Changes in epididymal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg | 0.005 mg | Affects uterine morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:12858341 | IVTH | 0.000000001 M | 0.000000001 M | Affects placental differentiation | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000001 M | 0.000000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:14636701 | IVR | 0.03 mg/kg | 0.03 mg/kg | Alterations in thymocytes population | Immunological endocrine-mediated perturbations |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Increase in uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:14695980 | IVR | 1 mg/kg/day | 1 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| PMID:14711791 | IVR | 0.1 mg | 0.1 mg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg | 0.1 mg | Changes in morphology of cervix | Reproductive endocrine-mediated perturbations | |
| PMID:14746342 | IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Decreased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| PMID:15016594 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:15019959 | IVR | 0.0003 mg/kg | - | No significant effects observed | - |
| IVR | 0.003 mg/kg | 0.003 mg/kg | Changes in Anteroventral periventricular Nucleus (AVPV) volume | Neurological endocrine-mediated perturbations | |
| PMID:15162385 | IVR | 0.04 M | 0.04 M | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| PMID:15166399 | IVR | 6 - 7 mg | 6 - 7 mg | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 6 - 7 mg | 6 - 7 mg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:15219628 | IVR | 0.5 mg/kg | 0.5 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| PMID:15315699 | IVR | 0.01 mg/day | 0.01 mg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.001 mg/day | 0.001 mg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000001 mg/day | - | No significant effects observed | - | |
| IVR | 0.0001 mg/day | 0.0001 mg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/day | 0.00001 mg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/day | 0.01 mg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:1537323 | IVR | 0.002 mg/wt/day | 0.002 mg/wt/day | Affects skeletal development | Developmental endocrine-mediated perturbations |
| PMID:15470002 | IVR | 0.05 mg | 0.05 mg | Affects lactation | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg | 0.05 mg | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg | 0.025 mg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00125 mg | - | No significant effects observed | - | |
| IVR | 0.025 mg | 0.025 mg | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0125 mg | 0.0125 mg | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0125 mg | 0.0125 mg | Decreased estrogen levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0125 mg | 0.0125 mg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0000125 mg | 0.0000125 mg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.000125 mg | 0.000125 mg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:15596228 | IVR | 0.00025 mg/kg | 0.00025 mg/kg | Alterations in thymocytes population | Immunological endocrine-mediated perturbations |
| IVR | 0.00025 mg/kg | 0.00025 mg/kg | Increased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Alterations in thymocytes population | Immunological endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Increased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Alterations in thymocytes population | Immunological endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Increased thymus gland weights | Immunological endocrine-mediated perturbations | |
| PMID:15597897 | IVTH | 0.000000004 M | 0.000000004 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:15751030 | IVR | 0.2 mg/day | 0.2 mg/day | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations |
| PMID:16439099 | IVR | 33 mg/kg | 33 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 33 mg/kg | 33 mg/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 33 mg/kg | 33 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 33 mg/kg | 33 mg/kg | Atrophy of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 33 mg/kg | 33 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 33 mg/kg | 33 mg/kg | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:16723702 | IVR | 0.002 mg | 0.002 mg | Accumulation of neutrophils in prostate gland | Immunological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.002 mg | 0.002 mg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Prostate hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Accumulation of lymphocytes in prostate gland | Immunological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:16759992 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| PMID:16819149 | IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| PMID:17010207 | IVR | 0.5 mg/kg | 0.5 mg/kg | Affects uterine contraction | Reproductive endocrine-mediated perturbations |
| PMID:17011747 | IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Uterotrophic effect | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects innate immunity | Immunological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Induce tumor progression | Endocrine-mediated cancer | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| PMID:17184923 | IVR | 0.0001 mg | 0.0001 mg | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.0001 mg | 0.0001 mg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:17213693 | IVR | 0.01 mg/day | 0.01 mg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/day | 0.01 mg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/day | 0.01 mg/day | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/day | 0.01 mg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/day | 0.001 mg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/day | 0.01 mg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/day | 0.01 mg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/day | 0.0001 mg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/day | 0.0001 mg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/day | 0.0001 mg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/day | 0.0001 mg/day | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/day | 0.0001 mg/day | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/day | 0.0001 mg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/day | 0.01 mg/day | Decreased weights of epididymis | Reproductive | |
| IVR | 0.0001 mg/day | 0.0001 mg/day | Affects steroidogenesis | ||
| IVR | 0.01 mg/day | 0.01 mg/day | Affects fertility | ||
| IVR | 0.01 mg/day | 0.01 mg/day | Decreased testis weights | ||
| IVR | 0.01 mg/day | 0.01 mg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | ||
| PMID:17229994 | IVR | 0.01 mg/kg | 0.01 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:17394237 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:17558187 | IVR | 0.04 mg/kg | 0.04 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:17679765 | IVR | 0.04 mg/kg | 0.04 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| PMID:18296022 | IVR | 1 mg/kg | 1 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | - | No significant effects observed | - | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| PMID:18692564 | IVR | 0.01 mg/kg | 0.01 mg/kg | Delayed puberty | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Alterations in preputial separation | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| PMID:18769493 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:19299448 | IVR | 0.01 mg/kg | 0.01 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVTH | 0.00000005 M | 0.00000005 M | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:19734697 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0015 mg/kg/day | 0.0015 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:19887736 | IVR | 1 mg/L | 1 mg/L | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations |
| IVR | 1 mg/L | 1 mg/L | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | - | No significant effects observed | - | |
| IVR | 100 mg/L | 100 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:20046027 | IVR | 1 mg/L | 1 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Decreased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Decreased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:20172022 | IVTH | 0.000001 - 0.000005 M | 0.000001 - 0.000005 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| PMID:20433902 | IVR | 3.4 mg/L | 3.4 mg/L | Abnormal neuronal distribution | Neurological endocrine-mediated perturbations |
| PMID:20815788 | IVR | 0.1 mg/L | 0.1 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/L | 0.1 mg/L | Increased ROS levels in sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.3 mg/L | 0.3 mg/L | Increased ROS levels in sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/L | 0.3 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| PMID:20932895 | IVR | 1.75 mg/kg/day | 1.75 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations |
| IVR | 1.75 mg/kg/day | 1.75 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.175 mg/kg/day | 0.175 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.175 mg/kg/day | 0.175 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.175 mg/kg/day | 0.175 mg/kg/day | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVR | 0.175 mg/kg/day | 0.175 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 1.75 mg/kg/day | 1.75 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 1.75 mg/kg/day | 1.75 mg/kg/day | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| PMID:21130156 | IVH | 2570 - 12400 mg | 2570 - 12400 mg | Affects embryonic development | Developmental endocrine-mediated perturbations |
| PMID:21761357 | IVR | 0.01 mg/kg | 0.01 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVTH | 0.0000000005 - 0.000005 M | 0.00000005 - 0.000005 M | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:22569274 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00005 mg/kg/day | 0.00005 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 0.00005 mg/kg/day | 0.00005 mg/kg/day | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| PMID:22679223 | IVR | 0.02 mg | 0.02 mg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.02 mg | 0.02 mg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:22710028 | IVR | 0.5 mg/kg | 0.5 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| PMID:23314658 | IVR | 0.0625 mg/kg/day | 0.0625 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.0625 mg/kg/day | 0.0625 mg/kg/day | Abnormal development of gonads in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0625 mg/kg/day | 0.0625 mg/kg/day | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0625 mg/kg/day | 0.0625 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| PMID:23454116 | IVR | 0.005 mg/kg | 0.005 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| PMID:23873838 | IVR | 0.17 mg/kg/day | 0.17 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.17 mg/kg/day | 0.17 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:24002655 | IVR | 1 mg/kg/day | 1 mg/kg/day | Affects innate immunity | Immunological endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:24316331 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Delayed puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Delayed puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:24449359 | IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Decreased body weights | Metabolic endocrine-mediated perturbations |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Causes inflammation | Immunological endocrine-mediated perturbations | |
| PMID:24533973 | IVTH | 0.0000001 M | 0.0000001 M | Induce cancer metastasis | Endocrine-mediated cancer |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Induce cancer metastasis | Endocrine-mediated cancer | |
| PMID:24578295 | IVR | 0.34 mg/kg | 0.34 mg/kg | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations |
| IVR | 0.34 mg/kg | 0.34 mg/kg | Affects corticosterone metabolism | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:24646703 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| PMID:25062584 | IVR | 0.05 mg/L | 0.05 mg/L | Affects implantation | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/L | - | No significant effects observed | - | |
| IVR | 0.02 mg/L | 0.02 mg/L | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/L | 0.02 mg/L | Affects implantation | Reproductive endocrine-mediated perturbations | |
| PMID:25242112 | IVR | 0.1 mg | 0.1 mg | Affects uterine function | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg | 0.1 mg | Uterine hyperplasia | Reproductive endocrine-mediated perturbations | |
| PMID:25243144 | IVR | 0.005 mg | 0.005 mg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 0.005 mg | 0.005 mg | Changes in T-cell populations | Immunological endocrine-mediated perturbations | |
| IVR | 0.005 mg | 0.005 mg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| PMID:25852458 | IVR | 0.0001 mg | 0.0001 mg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg | 0.0001 mg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:26349937 | IVR | 0.33 mg/kg | 0.33 mg/kg | Testicular atrophy | Reproductive endocrine-mediated perturbations |
| IVR | 0.33 mg/kg | 0.33 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.33 mg/kg | 0.33 mg/kg | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| PMID:26457333 | IVR | 1 mg/kg/day | 1 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations |
| PMID:26970683 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00005 mg/kg/day | 0.00005 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| PMID:27103539 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:27613106 | IVR | 0.01 mg/kg | 0.01 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:28031325 | IVTH | 0.00000000001 - 0.0001 M | 0.0000000001 - 0.0001 M | Affects calcium signaling in sperm | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000000001 - 0.0001 M | 0.0000000001 - 0.0001 M | Affects calcium signaling | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000000001 - 0.0001 M | 0.000001 - 0.0001 M | Affects peneration rate of sperms | Reproductive endocrine-mediated perturbations | |
| PMID:28078498 | IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:28265775 | IVR | 0.1 mg | 0.1 mg | Uterine hyperplasia | Reproductive endocrine-mediated perturbations |
| PMID:28734970 | IVR | 0.0005 mg/kg | 0.0005 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Accelerated onset of puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00005 mg/kg | 0.00005 mg/kg | Accelerated onset of puberty | Reproductive endocrine-mediated perturbations | |
| PMID:28970132 | IVR | 0.00005 mg/kg/day | 0.00005 mg/kg/day | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:29102757 | IVR | 25 mg | 25 mg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations |
| IVR | 25 mg | 25 mg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg | 25 mg | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| PMID:29752986 | IVR | 0.00001 mg/kg/day | 0.00001 mg/kg/day | Affects folliculogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:29931162 | IVR | 0.1 mg/kg | 0.1 mg/kg | Abnormal development of gonads in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30153466 | IVR | 5000 mg/kg | 5000 mg/kg | Alterations in thymocytes population | Immunological endocrine-mediated perturbations |
| PMID:31084616 | IVR | 0.002 mg/kg | 0.002 mg/kg | Increase in uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Increase in uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Increase in uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00025 mg/kg | - | No significant effects observed | - | |
| IVR | 0.004 mg/kg | 0.004 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.004 mg/kg | 0.004 mg/kg | Increase in uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:31283846 | IVR | 0.05 mg/rat/day | 0.05 mg/rat/day | Decreased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/rat/day | 0.05 mg/rat/day | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/rat/day | 0.05 mg/rat/day | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| PMID:31780364 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects implantation in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects spermatogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Reduced sperm counts in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:32370801 | IVR | 0.1 mg/kg | 0.1 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations |
| PMID:32545544 | IVR | 0.01 mg/day | 0.01 mg/day | Induce DNA damage in uterine cells | Reproductive endocrine-mediated perturbations |
| PMID:32592162 | IVR | 0.002 mg | 0.002 mg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.002 mg | 0.002 mg | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Increased estrogen levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:33012732 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Changes in brain morphology | Neurological endocrine-mediated perturbations |
| PMID:33571642 | IVR | 0.003 - 0.012 mg/kg/day | 0.003 - 0.012 mg/kg/day | Nipple retention | Reproductive endocrine-mediated perturbations |
| IVR | 0.003 - 0.021 mg/kg/day | 0.003 - 0.021 mg/kg/day | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 0.003 - 0.012 mg/kg/day | 0.003 - 0.012 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 0.003 - 0.012 mg/kg/day | 0.003 - 0.012 mg/kg/day | Changes in number of nipples | Reproductive endocrine-mediated perturbations | |
| IVR | 0.003 - 0.012 mg/kg/day | 0.003 - 0.012 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:33920546 | IVR | 0.125 mg/kg | 0.125 mg/kg | Decreased body weights | Metabolic endocrine-mediated perturbations |
| IVR | 0.125 mg/kg | 0.125 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.125 mg/kg | 0.125 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 0.125 mg/kg | 0.125 mg/kg | Increased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 0.125 mg/kg | 0.125 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:34207679 | IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased body weights | Metabolic endocrine-mediated perturbations |
| IVR | 0.00005 - 0.05 mg/kg | 0.00005 - 0.05 mg/kg | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| PMID:34831106 | IVTH | 0.00001 M | 0.00001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| PMID:35605701 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Epigenomic alterations in sperm | Reproductive endocrine-mediated perturbations | |
| PMID:35834052 | IVR | 0.002 mg/day | 0.002 mg/day | Affects ovarian development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| PMID:36096261 | IVR | 0.000375 mg/L | 0.000375 mg/L | Changes in testicular morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.000375 mg/L | 0.000375 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000375 mg/L | 0.000375 mg/L | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000375 mg/L | 0.000375 mg/L | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| PMID:36328762 | IVR | 0.002 mg/day | 0.002 mg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 0.002 mg/day | 0.002 mg/day | Epigenomic alterations in seminal vesicle | Reproductive endocrine-mediated perturbations | |
| PMID:36488194 | IVR | 0.002 mg/day | 0.002 mg/day | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects uterine development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Compromised endometrial receptivity | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects endometrial development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Increased estrogen levels | Reproductive endocrine-mediated perturbations | |
| PMID:36621641 | IVTH | 0.0000000001 - 0.000001 M | 0.0000000001 - 0.000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.000001 M | 0.0000000001 - 0.000001 M | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| PMID:36653537 | IVR | 0.003 - 0.012 mg/kg/day | 0.003 - 0.012 mg/kg/day | Affects ovarian development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:37077353 | IVR | 3 - 12 mg/kg/day | 3 - 12 mg/kg/day | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVR | 3 - 12 mg/kg/day | 3 - 12 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 6 - 12 mg/kg/day | 6 - 12 mg/kg/day | Affects calcium signaling | Metabolic endocrine-mediated perturbations | |
| IVR | 3 - 12 mg/kg/day | 3 - 12 mg/kg/day | Affects cell metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 3 - 12 mg/kg/day | 3 - 12 mg/kg/day | Increased gonadotropin-releasing hormone (GnRH) levels | Reproductive endocrine-mediated perturbations | |
| PMID:37268149 | IVR | 0.012 - 0.048 mg/kg/day | 0.012 - 0.048 mg/kg/day | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations |
| IVR | 0.012 - 0.048 mg/kg/day | 0.012 - 0.048 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| PMID:37471692 | IVR | 0.001 - 0.1 mg/kg | 0.001 - 0.1 mg/kg | Pregnancy complications | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 - 0.1 mg/kg | 0.05 - 0.1 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 - 0.1 mg/kg | 0.05 - 0.1 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 - 0.1 mg/kg | 0.05 - 0.1 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.001 - 0.1 mg/kg | 0.001 - 0.1 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 - 0.1 mg/kg | 0.001 - 0.1 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| PMID:37511399 | IVR | 0.01 mg | 0.01 mg | Causes inflammation | Immunological endocrine-mediated perturbations |
| PMID:37561284 | IVR | 0.002 mg/day | 0.002 mg/day | Induce tumor progression | Endocrine-mediated cancer |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/day | 0.002 mg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:37650943 | IVR | 0.01 mg | 0.01 mg | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg | 0.01 mg | Epigenomic alterations in uterine cells | Reproductive endocrine-mediated perturbations | |
| PMID:37689587 | IVR | 0.01 mg/day | 0.01 mg/day | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVR | 0.01 mg/day | 0.01 mg/day | Induce apoptosis of endometrial cells | Reproductive endocrine-mediated perturbations | |
| PMID:37779174 | IVR | 0.002 mg/day | 0.002 mg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| PMID:37854179 | IVR | 0.003 - 0.048 mg/kg/day | 0.003 - 0.048 mg/kg/day | Decreased body weights | Metabolic endocrine-mediated perturbations |
| IVR | 0.012 - 0.048 mg/kg/day | 0.012 - 0.048 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.012 - 0.048 mg/kg/day | 0.012 - 0.048 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.012 - 0.048 mg/kg/day | 0.012 - 0.048 mg/kg/day | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 0.012 - 0.048 mg/kg/day | 0.012 - 0.048 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.003 - 0.048 mg/kg/day | 0.003 - 0.048 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:37856394 | IVR | 1 mg/kg/day | 1 mg/kg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects uterine development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:39326550 | IVTH | 0.000000001 M | 0.000000001 M | Increased cortisone levels | Neurological endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Increased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:39730480 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| PMID:846001 | IVR | 0.01 mg/kg | - | No significant effects observed | - |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg | - | No significant effects observed | - | |
| IVR | 0.005 mg/kg | - | No significant effects observed | - | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Changes in morphology of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/kg | - | No significant effects observed | - | |
| IVR | 0.0025 mg/kg | - | No significant effects observed | - | |
| PMID:9472934 | IVR | 40 mg/kg | 40 mg/kg | Changes in morphology of accessory sex organs | Reproductive endocrine-mediated perturbations |
| IVR | 40 mg/kg | 40 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Changes in epididymal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.